Andreasenlist7617

XB130 is a novel adapter protein that behaves as a tumor promoter or suppressor mediating cell proliferation and metastasis in the development of different human tumors. Altered expression of XB130 has been verified in human non-small cell-lung cancer (NSCLC). However, the exact effect of XB130 on NSCLC is not well-understood. selleck compound In this study, we investigated the biological function and posttranscriptional regulation of XB130 in NSCLC. First, the effects of XB130 silence on NSCLC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) were examined. Then the targeting relationship between XB130 and miR-203, miR-219, or miR-4782-3p was demonstrated by dual-luciferase reporter assay. Finally, the effects of miR-203, miR-219, and miR-4782-3p on NSCLC cell function were studied, respectively. We found that XB130 silence significantly inhibited cell growth, migration and invasion, and reversed EMT. Furthermore, XB130 was posttranscriptionally regulated by miR-203, miR-219, and miR-4782-3p. Overexpression of miR-203, miR-219, or miR-4782-3p inhibited cell growth, migration and invasion, and reversed EMT, just like the role of XB130 in NSCLC cells, whereas the suppressive effects of microRNA (miRNA) overexpression were weakened by miRNA inhibitors or ectopic expression of XB130 in NSCLC cells. These data demonstrate that XB130 is posttranscriptionally regulated by miR-203, miR-219, and miR-4782-3p and mediates the proliferation and metastasis of NSCLC cells. © 2020 Wiley Periodicals, Inc.Peroxymonosulfate (PMS) heterogeneous activation by Co3 O4 -modified catalyst has shown significant implications to generate free radicals for organic pollutants degradation in water. In this study, PMS heterogeneous activation was applied to degrade atrazine (ATZ) using Co3 O4 -mediated titanium dioxide nanoparticles (Co3 O4 /TiO2 NPs), which were synthesized by sol-gel method. Firstly, characteristics of the fresh and used Co3 O4 /TiO2 NPs were analyzed via SEM, TEM, XRD, EDS, and XPS techniques. Then, the influences of several key parameters (i.e., Co3 O4 /TiO2 NPs dose (0.02 - 0.3 g/L), PMS dose (0 - 0.6 mM), initial pH (3.0 - 11.0), and co-existing anions) on the ATZ degradation were investigated systematically. Besides, control systems were set up to verify the high efficiency of Co3 O4 /TiO2 NPs. In addition, the radical scavenging experiments revealed that sulfate and hydroxyl radicals were generated in the Co3 O4 /TiO2 -PMS system, while sulfate radicals were the dominant reactive species responsible for ATZ degradation. Furthermore, the stability and reusability of the Co3 O4 /TiO2 NPs were investigated after four consecutive experiments. Based on the identified products, possible degradation pathways of ATZ in the Co3 O4 /TiO2 -PMS system were proposed. Finally, the possible reaction mechanism of Co3 O4 /TiO2 -PMS system was proposed according to the comprehensive analysis. Findings of this study provided useful information for the application of Co3 O4 /TiO2 NPs in recalcitrant organic contaminants degradation. This article is protected by copyright. All rights reserved.Autism spectrum disorder (ASD) is associated with various molecular mechanisms including copy number variants (CNVs). We investigated possible associations between CNVs and ASD clinical correlates. We evaluated pertinent physical characteristics and phenotypic measures such as cognitive level, severity of ASD symptoms and comorbid conditions in ASD patients consecutively recruited over the study period. Children with causative (C-CNVs), non-causative (NC-CNVs) and without CNVs (W-CNVs) were compared. Out of 109 patients, 31 imbalances (16 duplications and 15 deletions) were detected in 25 subjects. Seven (6.4%) had C-CNVs and 18 (16.5%) had NC-CNVs. Paired post hoc comparisons with Bonferroni adjustment showed that dysmorphisms and microcephaly were significantly more frequent in the C-CNVs group. Patients with C-CNVs had more severe autistic core symptoms, while comorbid internalizing behavioral symptoms were more represented among participants with NC-CNVs. No significant differences were observed for distribution of macrocephaly, intellectual disability, epilepsy, isolated electroencephalogram abnormalities and studied neuroimaging characteristics among groups. Recurrent and rare C-CNVs highlighting genes relevant to neurodevelopment had a statistically higher occurrence in children with more severe ASD symptoms and further developmental abnormalities. This study documents the importance of measuring the physical and neurobehavioural correlates of ASD phenotypes to unravel the underlying molecular mechanisms in patient subgroups. © 2020 International Society for Developmental Neuroscience.In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first-line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once daily in 28-day cycles, in patients with EGFR-activating mutation-positive (EGFR-positive; exon 19 deletion or exon 21 L858R substitution mutations) advanced non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS; RECIST, version 1.1, by blinded independent review). In 81 Japanese patients (40 dacomitinib, 41 gefitinib), PFS was longer with dacomitinib compared with gefitinib (hazard ratio [HR], 0.544 [95% confidence intervalCI, 0.307-0.961]; 2-sided P = .0327; median 18.2 for dacomitinib [95% CI, 11.0-31.3] months, 9.3 [95% CI, 7.4-14.7] months for gefitinib). The most common Grade 3 AEs were dermatitis acneiform with dacomitinib (27.5%) and increased alanine aminotransferase with gefitinib (12.2%). A higher proportion of patients receiving dacomitinib (85.0%) compared with gefitinib (24.4%) had AEs leading to dose reduction. Incidence and severity of diarrhea, dermatitis acneiform, stomatitis and paronychia were generally reduced after dacomitinib dose reductions and dacomitinib treatment duration was generally longer in patients with a dose reduction in comparison with those without a dose reduction. Our results confirm the efficacy and safety of first-line dacomitinib in Japanese patients with EGFR-positive advanced NSCLC. This article is protected by copyright. All rights reserved.